Sage Therapeutics Inc. has described sterol derivatives acting as glutamate receptor ionotropic, NMDA 2A (GRIN2A; GluN2A) negative allosteric modulators reported to be useful for the treatment of neurological disorders.

Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a pan-KRAS-targeting moiety through a linker.

Petra Pharma Corp. has identified phosphatidylinositol 3-kinase α (PI3Kα) E545K and H1047R mutant inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS).

Aligos Therapeutics Inc. and Katholieke Universiteit Leuven (KU Leuken) have synthesized antiviral compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome, norovirus and picornavirus infections.

Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Medicine Co. Ltd. have disclosed norbornene derivatives reported to be useful for the treatment of cerebral infarction, coronary heart disease, myocardial infarction and cerebral ischemia.

Zhongshan Innovation New Drug Development Co. Ltd. has described conjugates comprising a chelating ligand moiety, a fibroblast activation protein α (FAP) ligand and integrin αvβ3 or integrin αvβ6 ligand and a linker. They are reported to be potentially useful for the diagnosis and/or treatment of cancer.

Chinese Academy of Medical Sciences has divulged imidazopyridine derivatives reported to be useful for the treatment of Acinetobacter infections, particularly A. baumannii infections.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified salts of deuterated compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Simcere Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising E3 ubiquitin-protein ligands coupled to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety via a linker reported to be useful for the treatment of cancer and inflammatory disorders.

Bivision Pharmaceuticals (Shanghai) Co. Ltd. has disclosed peptide-drug conjugates reported to be useful for diagnosis and treatment of fibrosarcoma.